Skip to main content

Table 2 Subgroup analysis of mortality with cefazolin versus ASPs for the treatment of MSSA bacteremia

From: Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis

Variable No. of studies No. of patients OR (95% CI) P Value I2%
Study design
 Retrospective 8 4212 0.71 (0.59–0.84) 0.57 0
 Prospective 2 258 0.27 (0.09–0.79) 0.46 0
Location
 USA 5 3670 0.71 (0.59–0.86) 0.52 0
 Other 5 800 0.57 (0.36–0.91) 0.25 25.4
Study period
 Initiated before 2008 4 3782 0.58 (0.36–0.92) 0.15 43.4
 Initiated after 2008 6 688 0.71 (0.59–0.85) 0.64 0
Mortality recording time
 30-day mortality 6 3676 0.60 (0.48–0.75) 0.81 0
 90-day mortality 7 4133 0.69 (0.58–0.82) 0.30 16.9
Adjustment
 Propensity score matched or multiple adjusted 6 4040 0.69 (0.58–0.83) 0.26 23.6
 Unadjusted 10 4779 0.74 (0.64–0.87) 0.11 37.6
Control group
 NAF or OXA 7 3910 0.69 (0.57–0.83) 0.26 22.6
 CLX 3 560 0.69 (0.42–1.12) 0.46 0
  1. ASPs antistaphylococcal penicillins, CFZ cefazolin, CI confidence interval, CLX cloxacillin, MSSA methicillin-susceptible Staphylococcus aureus, NAF nafcillin, OR odds ratio, OXA oxacillin